Innate Pharma Announces the Appointment of Joyson Karakunnel, MD, MSC, FACP as Chief Medical Officer
16 Juillet 2020 - 7:00AM
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq:
IPHA) (“
Innate” or the “
Company”)
today announced the appointment of Dr. Joyson Karakunnel as
Executive Vice President and Chief Medical Officer (CMO). Dr.
Pierre Dodion, CMO since 2014, is retiring from this position.
Dr. Karakunnel comes to the Company with deep
experience in immuno-oncology, and a proven track record in drug
development. As CMO, he will be responsible for advancing Innate’s
clinical pipeline and will lead a global team focused on clinical
strategy, patient safety, regulatory and medical affairs.
Most recently, Dr. Karakunnel served as CMO and
Senior Vice President at Tizona Therapeutics, where he led the
development of the company’s biotherapeutics pipeline. Prior to
Tizona, he held positions with Arcus Biosciences and
AstraZeneca/MedImmune; his collective responsibilities included
leading clinical development activities, drug safety and regulatory
affairs. In addition, he serves as a medical advisor at the Parker
Institute for Cancer Immunotherapy.
“We are pleased to welcome Dr. Joyson Karakunnel
as our new Chief Medical Officer. As an experienced medical
oncologist, Joyson brings in-depth immunology, oncology and
hematology expertise, which will help further strengthen and
accelerate the delivery of new medicines to patients,” said
Mondher Mahjoubi, Chief Executive Officer of Innate
Pharma. “We are also grateful for Pierre’s invaluable
contributions. During his six years at Innate, he drove the
advancement of several key assets to late-stage clinical
development, which will have a lasting impact on the Company.”
Dr. Dodion joined Innate in 2014 and has been
instrumental in the Company’s clinical strategy, successfully
advancing key oncology programs to late-stage status. He has led
the clinical development of several therapeutic programs, including
monalizumab, a potentially first-in-class immune checkpoint
inhibitor, and lacutamab, a first-in-class antibody designed for
the treatment of advanced T-cell lymphomas. Dr. Dodion will
transition to a consulting role with Innate following his
retirement.
Dr. Joyson Karakunnel
Adding to his track record in oncology and
hematology drug development, Dr. Karakunnel also served as a
clinical trial investigator at the National Cancer Institute and a
team leader for the hematologic group at Walter Reed National
Military Medical Center. In addition, he was an associate professor
at the Uniformed Services University of the Health Sciences and a
medical reviewer at the U.S. Food and Drug Administration.
“I’m proud to join Innate at this exciting
juncture with several molecules moving into late-stage development,
new molecules moving into the clinic and novel indications being
pursued in oncology as well as for COVID-19,” said Joyson
Karakunnel, Chief Medical Officer of Innate Pharma. “This
is clearly a company with a robust pipeline and unique focus on the
innate immune system, which complements the work I’ve done in both
the academic and industry settings. I look forward to further
advancing the innovative science with the talented scientists and
clinicians at the Company.”
Dr. Karakunnel completed fellowships in
hematology and oncology at the National Cancer Institute and
completed his internal medicine residency at the University of
Medicine and Dentistry of New Jersey, where he was chief resident.
He obtained his MD from Annamalai University in India, and also
holds a MSc in pharmacology from the University of Maryland.
Dr. Karakunnel will be based in Innate’s
Rockville, Maryland office.
About Innate Pharma:
Innate Pharma S.A. is a commercial stage
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s commercial-stage product,
Lumoxiti, in-licensed from AstraZeneca in the US, EU and
Switzerland, was approved by the FDA in September 2018. Lumoxiti is
a first-in class specialty oncology product for hairy cell
leukemia. Innate Pharma’s broad pipeline of antibodies includes
several potentially first-in-class clinical and preclinical
candidates in cancers with high unmet medical need.
Innate has been a pioneer in the understanding
of natural killer cell biology and has expanded its expertise in
the tumor microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Based in Marseille, France, Innate Pharma is
listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at
www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN codeTicker
codeLEI |
FR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29 |
Disclaimer:
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995.The use of
certain words, including “believe,” “potential,” “expect” and
“will” and similar expressions, is intended to identify
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. These risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including related to safety, progression of and
results from its ongoing and planned clinical trials and
preclinical studies, review and approvals by regulatory authorities
of its product candidates, the Company’s commercialization efforts,
the Company’s continued ability to raise capital to fund its
development and the overall impact of the COVID-19 outbreak on the
global healthcare system as well as the Company’s business,
financial condition and results of operations. For an
additional discussion of risks and uncertainties which could cause
the company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2019,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
Investors Innate
Pharma Danielle Spangler Tel.: +1 917 499 6240
Danielle.Spangler@innate-pharma.com Tel.: +33 (0)4 30 30 30
30 investors@innate-pharma.com |
Media Innate Pharma
Tracy Rossin (Global/US) Tel.: +1 240 801 0076
Tracy.Rossin@innate-pharma.com ATCG
Press Marie Puvieux (France) Tel.: +33 (0)9 81 87 46 72
innate-pharma@atcg-partners.com |
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024